NASDAQ:OBIO Orchestra BioMed Q3 2026 Earnings Results & Report $5.73 +0.03 (+0.53%) Closing price 04:00 PM EasternExtended Trading$5.76 +0.03 (+0.61%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Orchestra BioMed beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.30 versus the -$0.40 consensus estimate, while revenue of $91 thousand fell short of the $129 thousand estimate by $38.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeAfter Market ClosesConference Call7:00 AM ET Orchestra BioMed EPS ResultsActual EPS-$0.30Consensus EPS -$0.40Beat/MissBeat by +$0.10One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersOrchestra BioMed Revenue ResultsActual Revenue$91 thousandExpected Revenue$129 thousandBeat/MissMissed by -$38.00 thousandYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Orchestra BioMed Q3 2026 Earnings FAQ Did Orchestra BioMed beat earnings estimates for Q3 2026? Orchestra BioMed (NASDAQ:OBIO) reported earnings of -$0.30 per share for Q3 2026, beating the consensus estimate of -$0.40. The report was announced on Tuesday, November 10, 2026. What was Orchestra BioMed's revenue for Q3 2026? Orchestra BioMed reported revenue of $91 thousand for Q3 2026, against a consensus estimate of $129 thousand. Orchestra BioMed Earnings HeadlinesOrchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business UpdatesNovember 10 at 4:10 PM | globenewswire.comOrchestra BioMed (OBIO) Projected to Release Earnings on MondayNovember 8 at 2:26 AM | americanbankingnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 10 at 1:00 AM | Weiss Ratings (Ad)Orchestra BioMed Prices $75 Million Common Stock OfferingNovember 6, 2026 | marketscreener.comMOrchestra BioMed Prices $75 Mln Offering At $5/Shr To Fund Pivotal TrialsNovember 6, 2026 | rttnews.comOrchestra BioMed Announces Pricing of Public OfferingNovember 5, 2026 | globenewswire.comSee More Orchestra BioMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email. Email Address About Orchestra BioMedOrchestra BioMed (NASDAQ:OBIO) is a clinical-stage biotechnology and medical device company focused on developing technologies for cardiovascular disease and other high-need medical conditions. The company uses a partnership-driven business model, collaborating with established medical device and healthcare companies to advance products through clinical development and toward commercialization. Its lead program is BackBeat Cardiac Neuromodulation Therapy, an investigational bioelectronic treatment intended to provide sustained reductions in blood pressure for patients with hypertension. The therapy is designed to work through an implantable device that modulates the autonomic nervous system and may be used in conjunction with cardiac rhythm-management systems. Orchestra BioMed is developing the program in collaboration with Medtronic. The company is also developing Virtue SAB, a drug-device combination designed to deliver a proprietary sirolimus formulation to blood vessels during balloon angioplasty. The technology is intended to help address restenosis and other complications associated with vascular interventions. Orchestra BioMed’s programs are being evaluated through clinical and regulatory processes in the United States and other international markets. Orchestra BioMed was formed through the combination of Orchestra BioMed and a special purpose acquisition company and began trading publicly on Nasdaq in 2023. The company is led by founder and Chief Executive Officer David Hochman, who also serves as chairman.View Orchestra BioMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
